Galera Therapeutics Analyst Ratings
Galera Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 11.15% | HC Wainwright & Co. | $6 → $0.3 | Downgrades | Buy → Neutral |
| 08/10/2023 | 85.25% | Piper Sandler | $6 → $0.5 | Downgrades | Overweight → Neutral |
| 07/17/2023 | 2123.05% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/22/2023 | 2123.05% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 02/21/2023 | 2123.05% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 02/16/2023 | 2493.55% | B of A Securities | $2 → $7 | Upgrades | Underperform → Buy |
| 02/16/2023 | 3605.08% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/27/2022 | 641.02% | B of A Securities | → $2 | Downgrades | Neutral → Underperform |
| 12/20/2021 | 7310.15% | Citigroup | $11 → $20 | Maintains | Buy |
| 12/15/2021 | 3605.08% | HC Wainwright & Co. | → $10 | Upgrades | Neutral → Buy |
| 12/15/2021 | 5457.61% | BTIG | → $15 | Upgrades | Neutral → Buy |
| 10/20/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/19/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/16/2020 | 5457.61% | Credit Suisse | $9 → $15 | Upgrades | Neutral → Outperform |
| 12/07/2020 | 5457.61% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 11/11/2020 | 3234.57% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 07/29/2020 | 2864.06% | Credit Suisse | $14 → $8 | Maintains | Neutral |
| 12/02/2019 | 11015.23% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 12/02/2019 | 5457.61% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 12/02/2019 | 7310.15% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 5087.11% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/16/2023 | 11.15% | HC Wainwright & Co. | 6 美元 → 0.3 美元 | 降級 | 買入 → 中性 |
| 08/10/2023 | 85.25% | 派珀·桑德勒 | 6 美元 → 0.5 美元 | 降級 | 超重 → 中性 |
| 07/17/2023 | 2123.05% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 03/22/2023 | 2123.05% | HC Wainwright & Co. | 10 美元 → 6 美元 | 維護 | 購買 |
| 02/21/2023 | 2123.05% | 派珀·桑德勒 | → 6 美元 | 啓動覆蓋開啓 | → 超重 |
| 02/16/2023 | 2493.55% | B of A 類證券 | $2 → 7 美元 | 升級 | 跑贏大盤 → 買入 |
| 02/16/2023 | 3605.08% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 05/27/2022 | 641.02% | B of A 類證券 | → 2 美元 | 降級 | 中性 → 跑贏大盤 |
| 2021 年 12 月 20 日 | 7310.15% | 花旗集團 | 11 美元 → 20 美元 | 維護 | 購買 |
| 2021 年 12 月 15 日 | 3605.08% | HC Wainwright & Co. | → 10 美元 | 升級 | 中性 → 買入 |
| 2021 年 12 月 15 日 | 5457.61% | BTIG | → 15 美元 | 升級 | 中性 → 買入 |
| 2021 年 10 月 20 日 | — | HC Wainwright & Co. | 降級 | 買入 → 中性 | |
| 10/19/2021 | — | BTIG | 降級 | 買入 → 中性 | |
| 2020 年 12 月 16 日 | 5457.61% | 瑞士信貸 | 9 美元 → 15 美元 | 升級 | 中性 → 跑贏大盤 |
| 12/07/2020 | 5457.61% | HC Wainwright & Co. | → 15 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/11/2020 | 3234.57% | 瑞士信貸 | 8 美元 → 9 美元 | 維護 | 中立 |
| 07/29/2020 | 2864.06% | 瑞士信貸 | 14 美元 → 8 美元 | 維護 | 中立 |
| 12/02/2019 | 11015.23% | BTIG | → 30 美元 | 啓動覆蓋開啓 | → 購買 |
| 12/02/2019 | 5457.61% | B of A 類證券 | → 15 美元 | 啓動覆蓋開啓 | → 購買 |
| 12/02/2019 | 7310.15% | 花旗集團 | → 20 美元 | 啓動覆蓋開啓 | → 購買 |
| 12/02/2019 | 5087.11% | 瑞士信貸 | → 14 美元 | 啓動覆蓋開啓 | → 中立 |
What is the target price for Galera Therapeutics (GRTX)?
Galera Therapeutics（GRTX）的目標價格是多少？
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by HC Wainwright & Co. on August 16, 2023. The analyst firm set a price target for $0.30 expecting GRTX to rise to within 12 months (a possible 11.15% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月16日公佈了Galera Therapeutics（納斯達克股票代碼：GRTX）的最新目標股價。這家分析公司將目標股價定爲0.30美元，預計GRTX將在12個月內上漲至11.15％（可能上漲11.15％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Galera Therapeutics (GRTX)?
分析師對Galera Therapeutics（GRTX）的最新評級是多少？
The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by HC Wainwright & Co., and Galera Therapeutics downgraded their neutral rating.
Galera Therapeutics（納斯達克股票代碼：GRTX）的最新分析師評級由HC Wainwright & Co. 提供，Galera Therapeutics下調了中性評級。
When is the next analyst rating going to be posted or updated for Galera Therapeutics (GRTX)?
Galera Therapeutics（GRTX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Galera Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Galera Therapeutics的最後一次評級是在2023年8月16日提交的，因此你應該預計下一個評級將在2024年8月16日左右公佈。
Is the Analyst Rating Galera Therapeutics (GRTX) correct?
分析師對 Galera Therapeutics (GRTX) 的評級正確嗎？
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a downgraded with a price target of $6.00 to $0.30. The current price Galera Therapeutics (GRTX) is trading at is $0.27, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Galera Therapeutics（GRTX）評級被下調，目標股價爲6.00美元至0.30美元。Galera Therapeutics（GRTX）目前的交易價格爲0.27美元，超出了分析師的預測區間。